Latest Biosensors International Stories
Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment...
According to a new market report published by Transparency Market Research "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for interventional cardiology devices was calculated at USD 15.8 billion in 2011 and is expected to grow...
SOMERSET, N.J., Feb. 19, 2013 /PRNewswire/ -- Terumo Interventional Systems, a business unit of Terumo Medical Corporation, today announced the launch of a new, dedicated group focused on direct sales, marketing, support and distribution of key products to the urological specialty beginning April 1, 2013. The move is part of the company's commitment to strengthening a direct relationship with urologists nationwide that currently use its market-leading GLIDEWIRE® Hydrophilic...
SOMERSET, N.J., Feb. 19, 2013 /PRNewswire/ -- Terumo Medical Corporation (Terumo), today announced that it has filed a patent infringement lawsuit against Vascular Solutions Inc. and Lepu Medical Technology (Beijing) Co., Ltd in the U.S. District Court of New Jersey. The complaint alleges that R Band(TM) Radial Hemostasis Device distributed by Vascular Solutions and manufactured by Lepu Medical Technology infringes on a patent and trademark, which Terumo Medical Corporation holds...
SINGAPORE, Feb. 7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, has announced a collaboration with Terumo Corporation to promote the Nobori(TM) drug-eluting stent (DES) system at specific specialist cardiology centers in Japan. Nobori incorporates two elements of Biosensors-developed technology: Biolimus A9(TM)...
SINGAPORE, Feb. 7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its third fiscal quarter ("Q3 FY13") and nine months ended 31 December 2012 ("FY13 nine-month period"). Financial Performance and Recent Highlights: In January, Biosensors received CE Mark approval for its...
SINGAPORE, Jan. 28, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom(TM). BioFreedom represents the latest development in Biosensors' stent technology, featuring a micro-structured abluminal surface which permits the controlled release of...
Global Trial Led by Dr. Dean Kereiakes of Lindner Research Center CINCINNATI, Dec. 3, 2012 /PRNewswire-USNewswire/ -- Clinical scientists at The Christ Hospital's Lindner Research Center are leading a worldwide study evaluating new breakthrough coronary stent technology that may make stenting easier and safer. The first procedures to implant the novel SYNERGYâ"¢ stent were performed at The Christ Hospital by Drs. Thomas Broderick and Joseph Choo, interventional cardiologists....
SINGAPORE, Nov. 7, 2012 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of fiscal year 2013 (Q2 FY13) and the fiscal six months ended 30 September 2012 (H1 FY13). Q2 FY13 and Recent Highlights: Total revenue of US$79.8 million, representing 28% year-on-year growth...
DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), as well as potential additional biomedical products. The patent rights are assigned to...
